Skip to main content
Premium Trial:

Request an Annual Quote

Sure, It's a Silly Name. But You Won't Be Laughing When You Sign a $350,000 Check

Unless you were stuck under an autoclave yesterday, you've heard that another personal genomics company, Knome, announced that it was open for business.

For the bloggers' perspective, you can check out any number of sites. Bertalan Meskó jumps in with a review of Knome's website, scientific advisors, and business model -- and concludes that skepticism reigns "as Knome doesn't say a word about how they can connect the data of whole-genome sequencing to the future of my health."

Over at VentureBeat, David Hamilton has a two-part analysis of Knome, which is essentially charging customers $350,000 to have their genome sequenced. (Sure, it's pricey. But, hey, Christmas is just around the corner.) Hamilton writes, "Don't be surprised to hear critics kvetch about 'celebrity genomics' or knock Knome for catering to the rich and famous once the word gets out." Go here for part 1 and here for part 2.

 

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.